Veradermics, Incorporated

Veradermics, Incorporated is a dermatologist-founded, late clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut. The company's core mission is to bring clarity, evidence, and medical progress to hair loss care, aiming to transform the treatment of pattern hair loss through rigorous science and thoughtful innovation. Founded in 2019, Veradermics focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions.

The company's lead product candidate is VDPHL01, an oral, non-hormonal treatment for both men and women experiencing pattern hair loss (PHL). VDPHL01 is an oral, extended-release (ER) proprietary formulation of minoxidil, engineered to maximize hair growth while minimizing the risk of cardiac activity. Veradermics aims to develop a focused portfolio of aesthetic dermatology product candidates, with potential selective development of medical dermatology product candidates.

Veradermics recently announced positive topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial (Study '302') evaluating VDPHL01 in males with mild-to-moderate pattern hair loss. The study demonstrated rapid and robust hair growth, meeting all primary and key secondary endpoints with a favorable safety profile. These results position VDPHL01 as a potential first FDA-approved oral pill for pattern hair loss in nearly 30 years. The company, led by CEO Reid Waldman, M.D., completed an upsized public offering and private placement in late April and early May 2026, raising significant capital to advance its programs.